Table 1.
Study | Reference | Number of patients | Enrollment (mm/yyyy) |
Event status |
Median follow upa (Range; years) | Number alive at last contact | |
---|---|---|---|---|---|---|---|
Start | End | No event | |||||
HB 89 | VonSchweinitz 1995 [14] | 72 | 3/1988 | 10/1993 | 53 | 4.7 (1.6–5.7) | 56 |
HB 99 | Haeberle 2003 [15] | 141 | 1/1999 | 12/2008 | 103 | 5.4 (1.5–10.6) | 110 |
INT0098 | Ortega 2000 [11] | 170 | 8/1989 | 12/1992 | 108 | 10.3 (0.9–19.2) | 120 |
JPLT 1 | Sasaki 2002 [16] | 106 | 12/1990 | 11/1997 | 72 | 5.7 (0.9–16.8) | 79 |
JPLT 2 | Hishiki 2011 [17] | 298 | 4/1999 | 12/2010 | 212 | 4.0 (0.2–12.5) | 243 |
P9645 | Malogolowkin 2006 [18]; Katzenstein 2009 [13] | 277 | 4/1999 | 11/2006 | 190 | 7.9 (0–11.7) | 219 |
SIOPEL 2 | Perilongo 2004 [8] | 135 | 11/1995 | 5/1998 | 97 | 7.4 (0.2–9.4) | 100 |
SIOPEL 3 | Perilongo 2009 [9] | 406 | 7/1998 | 12/2006 | 319 | 5.0 (0.2–10.9) | 334 |
Overall | 1605 | 3/1988 | 12/2010 | 1154 | 5.9 (0–19.2) | 1271 |
For patients without an EFS-event.